HIV treatment: latest news

HIV treatment resources

HIV treatment features

HIV treatment in your own words

HIV treatment news from aidsmap

More news

HIV treatment news selected from other sources

  • Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat for People Living with HIV-1

    If approved, atazanavir sulfate and cobicistat could offer patients living with HIV-1 a single tablet that eliminates the need to take a boosting agent in a separate tablet. Cobicistat is developed by Gilead Sciences, Inc.

    15 April 2014 | Bristol-Myers Squibb press release
  • Get More from Your Medical Care: Seven Resources Show You How

    How can you fit medical regular appointments into your life—and get more out of them? The seven resources below can help you understand how doctors think, boost communication with your medical provider (or find a new one), and keep up with regular appointments.

    14 April 2014 | BETA blog
  • India: Govt HIV treatment programme completes 10 years

    The anti-retroviral treatment (ART) covers 768,000 people but challenges in tackling the AIDS virus remain.

    11 April 2014 | Live Mint
  • Can Gilead Dominate The HIV Drug Market Again in 2014?

    The development of combination therapies provides Gilead with a long-lasting HIV product portfolio that should allow the company to maintain its leadership for the foreseeable future. As a result, Gilead is able to reinvest in its product portfolio.

    13 March 2014 | Motley Fool
  • Viral load rebounds in 35% of people using PI/r monotherapy: results of five-year PIVOT study

    A long-term strategy study sponsored by the Medical Research Council (MRC) in the UK reported low rates of serious complications and the potential to reduce drug costs. However, more than a third of people on the PI/r monotherapy group had viral load rebound compared to only 3% of people on standard combination therapy.

    10 March 2014 | HIV i-Base
  • UK: Once-daily HIV pill Tivicay from ViiV gets launch

    In England the drug is only available via private prescription until a decision on NHS funding is reached.

    05 February 2014 | Pharma Times
  • Antiretroviral treatment French guidelines 2013: economics influencing science

    In the new French guidelines, economic considerations significantly influence and, in some instances, take precedence over the scientific evidence, leading to guidelines that are significantly different from those of other national and international committees.

    27 January 2014 | Journal of Antimicrobial Chemotherapy
  • Quality Of Evidence Used By FDA To Approve New Drugs Varies Widely

    As the FDA seeks to approve drugs not only more quickly but also accommodate a growing clamor to exhibit more flexibility for endorsing therapies for life-threatening diseases, a curious wrinkle has emerged – there is a wide variation in the quality of underlying evidence used for approvals.

    22 January 2014 | Forbes
  • HIV/AIDS Editors' Choice: Top Stories of 2013

    The biggest change in HIV treatment over the past year has been the continued emergence of integrase inhibitor–based regimens as top options for first-line therapy.

    06 January 2014 | NEJM Journal Watch
  • A Year-End Look At HIV Treatments in 2013

    Looking ahead into 2014, convenient combination treatments like Gilead's Stribild could substantially improve the daily lives of patients. In addition, newer integrase inhibitors like Isentress and Tivicay could chip away at the dominance of Viread-based drugs. HIV vaccines, now nearly three decades overdue, could eventually arrive as well. RV 144 and Inovio's HIV vaccines are two promising projects which could eventually save millions of lives and render HIV cocktail drugs from Gilead and ViiV Healthcare obsolete.

    29 December 2013 | Motley Fool
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.